Industry
Biotechnology
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Loading...
Open
0.53
Mkt cap
112M
Volume
2.9M
High
0.55
P/E Ratio
-6.32
52-wk high
1.61
Low
0.50
Div yield
N/A
52-wk low
0.50
Portfolio Pulse from
November 21, 2024 | 3:45 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 12:47 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:42 pm
Portfolio Pulse from saritha@benzinga.com
August 08, 2024 | 9:22 pm
Portfolio Pulse from Benzinga Newsdesk
July 02, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 9:03 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 6:13 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 2:40 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.